Max-Planck-Gesellschaft
The Max Planck Institute for Terrestrial Microbiology (MPI-TM), part of the Max-Planck-Gesellschaft, is a publicly funded research institute in Marburg, Germany, employing 300+ researchers across molecular and synthetic microbiology, with proprietary enzyme technologies for CO2 fixation and natural product biosynthesis serving academic and industry collaborators.
- Company typePrivate
- Founded1948
- HeadquartersMarburg, Germany
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Max-Planck-Gesellschaft does
Max-Planck-Gesellschaft, operating through its Max Planck Institute for Terrestrial Microbiology (MPI-TM), is a German non-profit research organization headquartered in Marburg that conducts fundamental and applied research in molecular and synthetic microbiology. Founded in 1948 as part of the broader Max Planck Society network of over 86 institutes, MPI-TM investigates microbial metabolism of greenhouse gases, biosynthesis of bioactive natural compounds, cellular communication and regulation networks, and synthetic biological approaches to engineer microorganisms. The institute operates three research departments (Biochemistry and Synthetic Metabolism led by Tobias Erb; Natural Products in Organismic Interactions led by Helge Bode; Systems and Synthetic Microbiology led by Victor Sourjik), multiple Max Planck Research Groups, and department-independent groups, employing over 300 researchers from more than 35 countries.
The institute's core technology platforms center on proprietary enzyme and pathway engineering, including Fe nitrogenase for light-driven CO2 reduction to formate and methane, synthetic carboxylation modules and the Lactyl-CoA mutase (developed via adaptive laboratory evolution with 5-10x performance gains over natural precursors), the XUT cross-unit technology for assembling NRPS/PKS hybrid natural products such as syrbactins, and high-throughput synthetic biology pipelines supported by the MaxGENESYS biofoundry and core facilities in flow cytometry, mass spectrometry, metabolomics, and NMR. Research outputs are distributed through peer-reviewed publications in top-tier journals, technology transfer projects (HAPPY, DynaPore), the pan-European SynCell-nExUs postdoctoral program, and shared core facility services for external researchers.
MPI-TM operates under a non-profit, publicly funded business model. It receives core institutional support from the Max Planck Society, jointly financed by German federal and state governments, supplemented by competitive third-party grants from the European Research Council (ERC Advanced and Starting Grants), the Hessian LOEWE excellence program (4.78M EUR for the 2023-2026 Tree-M project), the Human Frontiers Science Program, and other scientific foundations. Revenue is not commercially generated through product or service sales; core facility access and transfer projects represent quasi-applied revenue channels rather than commercial monetization. The institute does not pursue an IPO and has no private shareholders, with strategic direction oriented toward scientific output, talent development, and translational research outcomes rather than financial returns.
Max-Planck-Gesellschaft firmographics
Firmographics- Name
- Max-Planck-Gesellschaft
- Legal name
- Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Website
- https://mpi-marburg.mpg.de
- Company type
- Private
- Founded year
- 1948
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- The Max Planck Institute for Terrestrial Microbiology (MPI-TM), part of the Max-Planck-Gesellschaft, is a publicly funded research institute in Marburg, Germany, employing 300+ researchers across molecular and synthetic microbiology, with proprietary enzyme technologies for CO2 fixation and natural product biosynthesis serving academic and industry collaborators.
- Ownership category
- akta.pro rank
Max-Planck-Gesellschaft industry classification
Industry- Product category
- Microbiology Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Microbiome & Metagenomics Services (HLAGANAH)
- akta.pro secondary industries
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)
Keywords
Where Max-Planck-Gesellschaft is headquartered
LocationHeadquarters
- HQ city
- Marburg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Max-Planck-Gesellschaft business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Government Funding: Funded by the Max Planck Society and German federal/state government research funding programs including LOEWE (Hessian excellence program)
- European Research Council Grants: ERC Advanced Grant and ERC Starting Grant funding for specific research projects
- Third-party Research Funding: Funding from programs like LOEWE (4.78 million euros for Tree-M project), Human Frontiers Science Grant, and other international research programs
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Max-Planck-Gesellschaft product offering
Product offeringCore offering
The Max Planck Institute for Terrestrial Microbiology conducts basic research on molecular and synthetic microbiology spanning microbial metabolism of greenhouse gases, bioactive natural compounds, cellular communication, and synthetic biology approaches. Its externally accessible offering is centered on shared core facility services (Flow Cytometry & Imaging, Mass Spectrometry & Proteomics, Metabolomics, NMR, MaxGENESYS biofoundry) used by academic and industry collaborators, complemented by research training programs.
Product overview
The Max Planck Institute for Terrestrial Microbiology (MPI-TM) is a leading European research institute in molecular and synthetic microbiology, not a commercial product company. Its offerings consist of shared research infrastructure (Core Facilities) providing specialized scientific services, research programs, and educational initiatives. Core facilities include Flow Cytometry & Imaging, Mass Spectrometry & Proteomics, Metabolomics & Small Molecules MS, Natural Product Isolation and NMR, MaxGENESYS high-throughput biofoundry, and SYNMIKRO Facilities. The institute operates transfer projects (HAPPY, DynaPore), participates in the Microbes for Climate (M4C) Cluster of Excellence, and hosts the Microcosm Earth Center (MEC) jointly with Philipps University of Marburg. Educational offerings include the IMPRS graduate school for doctoral training.
Differentiator
Problem solved
Functional benefit
Brands
- SYNMIKRO: Center for Synthetic Microbiology - an interdisciplinary research center affiliated with Philipps University of Marburg
- Microcosm Earth Center (MEC)
- Microbes for Climate (M4C)
Products and services
- Flow Cytometry & Imaging Flow cytometry and microscopy imaging services for microbial cell analysis, available to external academic and industry researchers as a shared Core Facility.
- Mass Spectrometry & Proteomics Mass spectrometry-based proteomics and protein analysis services available to external researchers through the institute's Core Facilities.
- Metabolomics & Small Molecules MS Metabolomics analysis and small molecule mass spectrometry services accessed by internal and external researchers for microbial and biochemical studies.
- Natural Product Isolation and NMR NMR-based isolation and structural characterization of natural products, supporting microbial drug discovery efforts run by internal and external research groups.
- MaxGENESYS biofoundry High-throughput screening biofoundry platform providing automated workflows for synthetic biology and metabolic engineering research projects.
Quantifiable outcome
- Development of new-to-nature carboxylation module improving CO2 fixation efficiency
- +3 more outcomes
Companies that use Max-Planck-Gesellschaft
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Max-Planck-Gesellschaft technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Max-Planck-Gesellschaft partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- Max Planck Institute of BiochemistrycoreCo-coordinator of SynCell-nExUs pan-European postdoctoral program offering 40 postdoctoral positions across 22 research institutions in 9 European countries starting August 1, 2026 for a duration of 5 years.
- Philipps-Universität MarburgcoreLong-standing collaboration through SYNMIKRO (Center for Synthetic Microbiology), Microcosm Earth Center (MEC), and Microbes for Climate (M4C) Cluster of Excellence. Joint projects include Tree-M LOEWE focus and multiple research groups.
- SYNMIKRO (Center for Synthetic Microbiology)coreAffiliated center dedicated to synthetic microbiology research, providing interdisciplinary cooperation hub in Marburg's microbiological research landscape.
- Microcosm Earth Center (MEC)coreFuture Center addressing current issues of environmental and climate microbiology with 7-year initial duration, financially supported by the state of Hesse. Coordinates with Max Planck Institute and hosts multiple research groups.
- Justus-Liebig Universität GießenmajorProject partner in LOEWE Tree-M priority (4.78 million euros funding 2023-2026) investigating leaf microbiome of trees for sustainable forest conservation strategies.
- Max Planck Institute for Molecular Plant Physiology (Potsdam)majorCollaboration on Lactyl-CoA mutase research for new-to-nature CO2-dependent acetyl-CoA assimilation, published in Nature Communications.
- TU MunichmajorCollaboration with Prof. Groll on XUT technology and immunoproteasome research for developing selective drug candidates against immune disorders using syrbactin-based hybrids.
- University of Duisburg-EssenmajorCollaboration with Prof. Kaiser on synthetic biology approaches for drug development and natural product engineering.
- Max Planck Institute for Marine Microbiology (Bremen)majorSister institute collaboration; Dr. Judith Klatt previously worked there before establishing research group at Microcosm Earth Center. Ongoing scientific exchange in marine and environmental microbiology.
- University of Wisconsin-MadisonminorJoint research on RNA biology through Campus Focus 'Microorganisms and Viruses' of Central Hesse Research Campus.
- Chinese Academy of SciencesmajorMax Planck-Chinese Academy Center for Synthetic Biochemistry established for natural product research collaboration with Chinese partners.
- 22 European Research InstitutionsmajorParticipating institutions in SynCell-nExUs program across 9 European countries, including leading universities and research centers in synthetic biology.
Scale indicators6 records
Recent moves10 records
Expansion highlights6 records
Max-Planck-Gesellschaft competitors and assessment
Company assessmentDirect peers
- ETH Zurich Department of Biology: Leading European research university with strong synthetic biology and microbiology programs. Competes directly with MPI-TM for ERC funding, faculty recruitment, and top-tier publication output in molecular microbiology and CO2 fixation.
- European Molecular Biology Laboratory (EMBL): Intergovernmental research organization in molecular life sciences with overlapping research in synthetic biology, structural biology, and microbial genomics. Comparable funding model and European scientific mission.
- Institut Pasteur: Leading French non-profit research institute with deep programs in microbiology, infectious disease, and molecular biology. Competes with MPI-TM for European funding, EMBO-affiliated talent, and high-impact publications.
- Weizmann Institute of Science: Israeli research university with strong departments in biochemistry, molecular genetics, and microbial sciences. Comparable in scale, mission, and research output to MPI-TM, often publishing in the same top-tier journals.
- Broad Institute: US-based joint Harvard-MIT institute with significant synthetic biology and microbiome research programs. Competes globally for talent, grants, and high-impact publications in molecular biology and engineering biology.
- MRC Laboratory of Molecular Biology: UK-based government research laboratory with foundational contributions to molecular biology and synthetic biology. Competes with MPI-TM for top-tier scientific talent and breakthrough publications.
- Max Planck Institute of Biochemistry: Sister Max Planck institute in Martinsried, co-coordinator of the SynCell-nExUs postdoctoral program. Operates overlapping research in molecular biology, biochemistry, and synthetic biology, sharing talent pipelines and infrastructure.
Others
- Novonesis (Novozymes): Industrial biotechnology company that commercializes enzymes and microbial solutions at scale. Represents the commercial translation pathway for academic discoveries in enzyme engineering and synthetic metabolism from MPI-TM.
Emerging players
- Joint BioEnergy Institute (JBEI): DOE-funded US research institute focused on synthetic biology for biofuels and bioproducts, with overlapping research on CO2 utilization and engineered metabolism. Represents a more application-oriented research model.
Broad incumbents
- Scripps Research Institute: Large US non-profit research organization with broad programs in chemistry, biology, and translational medicine. Has overlapping capabilities in natural product discovery and synthetic biology but operates a much wider research portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Max-Planck-Gesellschaft social profiles
Digital presenceMax-Planck-Gesellschaft financial estimates
Financial estimateRevenue estimate
Valuation estimate
Max-Planck-Gesellschaft leadership team
Management profileNumber of profiles
Profiles5 records
Max-Planck-Gesellschaft subsidiaries and ownership
Company hierarchySubsidiaries2 records
Max-Planck-Gesellschaft funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Max-Planck-Gesellschaft M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Max-Planck-Gesellschaft
What does Max-Planck-Gesellschaft do?
The Max Planck Institute for Terrestrial Microbiology conducts basic research on molecular and synthetic microbiology spanning microbial metabolism of greenhouse gases, bioactive natural compounds, cellular communication, and synthetic biology approaches. Its externally accessible offering is centered on shared core facility services (Flow Cytometry & Imaging, Mass Spectrometry & Proteomics, Metabolomics, NMR, MaxGENESYS biofoundry) used by academic and industry collaborators, complemented by research training programs.
Is Max-Planck-Gesellschaft a public or private company?
Max-Planck-Gesellschaft is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Max-Planck-Gesellschaft founded?
Max-Planck-Gesellschaft was founded in 1948. It employs 101 to 250 people.
Where is Max-Planck-Gesellschaft based?
Max-Planck-Gesellschaft is headquartered in Marburg, Germany, in the Europe region.
How does Max-Planck-Gesellschaft make money?
Three revenue lines are on record. Government Funding is the primary driver. The others are european Research Council Grants and third-party Research Funding.
Who are Max-Planck-Gesellschaft's main competitors?
Direct peers on record are ETH Zurich Department of Biology, European Molecular Biology Laboratory (EMBL), Institut Pasteur, Weizmann Institute of Science, Broad Institute, MRC Laboratory of Molecular Biology and Max Planck Institute of Biochemistry. Novonesis (Novozymes) is listed as an others. Joint BioEnergy Institute (JBEI) is listed as an emerging player. Scripps Research Institute is listed as a broad incumbent.
Does Max-Planck-Gesellschaft have an API?
No public API is recorded for Max-Planck-Gesellschaft.
What industry is Max-Planck-Gesellschaft in?
Max-Planck-Gesellschaft's product category is Microbiology Research Services. Its primary akta.pro industry code is HLAGANAH, Microbiome & Metagenomics Services, with a secondary code of HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 541714 and its SIC code is 8731.